BGLC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioNexus Gene Lab Corp (BGLC) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to support a buy decision. Holding off on investment is recommended until stronger signals or improvements in financials and sentiment emerge.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 38.379, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 2.23, with key support at 2.168 and resistance at 2.291.
Gross margin increased by 19.66% YoY in the latest quarter, indicating some operational efficiency improvements.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Technical indicators are bearish, and there are no AI Stock Picker or SwingMax signals.
In Q3 2025, revenue decreased to $2,543,823 (-3.29% YoY), net income dropped to -$708,991 (-47.30% YoY), and EPS fell to -$0.39 (-48.00% YoY). However, gross margin improved to 14.85% (+19.66% YoY).
No analyst ratings or price target changes available for this stock.
